3. Navigating Scans • Dr. Delphine Chen, Fred Hutch Cancer Center • Neuroendocrine Cancer Foundation
In this session from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, Dr. Delphine Chen, nuclear medicine physician at Fred Hutch Cancer Center and the University of Washington, presents “Navigating Scans.” Dr. Chen explains how imaging is used in the diagnosis, staging, monitoring, and treatment planning of neuroendocrine tumors. She discusses commonly used imaging tools, including CT, MRI, and Dotatate PET, and explains why different scans may be recommended depending on the location and biology of the tumor. This presentation covers the role of multiphase contrast CT and MRI in identifying liver metastases, how Dotatate PET can help detect well-differentiated neuroendocrine tumors, and how imaging may be used to assess eligibility for peptide receptor radionuclide therapy (PRRT). Dr. Chen also discusses surveillance imaging, treatment monitoring, scan frequency, and the importance of interpreting imaging results within the context of each patient’s care plan. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net.
In this session from the Neuroendocrine Cancer Foundation’s 2026 Virtual Annual Patient Conference, Dr. Delphine Chen, nuclear medicine physician at Fred Hutch Cancer Center and the University of Washington, presents “Navigating Scans.” Dr. Chen explains how imaging is used in the diagnosis, staging, monitoring, and treatment planning of neuroendocrine tumors. She discusses commonly used imaging tools, including CT, MRI, and Dotatate PET, and explains why different scans may be recommended depending on the location and biology of the tumor. This presentation covers the role of multiphase contrast CT and MRI in identifying liver metastases, how Dotatate PET can help detect well-differentiated neuroendocrine tumors, and how imaging may be used to assess eligibility for peptide receptor radionuclide therapy (PRRT). Dr. Chen also discusses surveillance imaging, treatment monitoring, scan frequency, and the importance of interpreting imaging results within the context of each patient’s care plan. Learn more about the Neuroendocrine Cancer Foundation and access patient resources at www.NCF.net.